As per DelveInsight, Chimeric Antigen Receptor T-Cell Therapy (CAR-T) market is expected to evolve immensely in the coming years owing to the increasing incidence of cancer types (ALL, NHL, MM, Prostate cancer, breast cancer, among others) and the ongoing research and development activities in the therapeutics landscape.
“Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Pipeline Insight, 2022” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the CAR T-Cell Therapy Market.
The CAR T-Cell Therapy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.
The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into emerging CAR T-Cell Therapies and the aggregate therapies developed by major pharma companies.
-
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development.
-
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the CAR T-Cell Therapy market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
This report covers around 300+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I), along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Learn How the Ongoing Clinical & Commercial Activities will Affect the CAR T-Cell Therapy Therapeutic Segment:
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Therapeutics Landscape
Chimeric Antigen Receptor (CAR) T Cell Therapy is an immunotherapy used for cancer treatment. In this therapy, T cells from the patient’s body are isolated and inserted in the CAR resulting in a specific receptor to bind to a specific protein in the patient’s cancer cells. CAR-T cell therapy is a remarkably promising treatment for cancer patients. This emerging treatment is one of the biggest breakthroughs since the introduction of chemotherapy.
Globally, about 300+ key companies are working in the Chimeric Antigen Receptor T-Cell Therapy (CAR-T) therapeutics segment.
Some of the key companies in the Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Market Include:
-
Shanghai Unicar-Therapy Bio-medicine Technology
-
Bluebird Bio
-
Cartesian Therapeutics
-
Autolus Limited
-
BioAtla
-
Miltenyi Biomedicine
-
Bellicum Pharmaceuticals
-
Poseida Therapeutics
-
Minerva Biotechnologies
-
JW Therapeutics
-
Wugen
-
Sorrento Therapeutics
-
Cartesian Therapeutics
-
CASI Pharmaceuticals/Juventas Cell Therapy
-
Novartis
-
Gilead Sciences
And many others
CAR-T Drugs Covered in the report include:
-
JWCAR029: JW Therapeutics
-
CEA CAR T: Sorrento Therapeutics
-
Descartes-11: Cartesian Therapeutics
-
CNCT19: CASI Pharmaceuticals/Juventas Cell Therapy
-
CTL119: Novartis
-
KTE-X19: Gilead Sciences
-
CART-19/22: Shanghai Unicar-Therapy Bio-medicine Technology
-
bb21217: Bluebird Bio
-
Descartes-08: Cartesian Therapeutics
-
AUTO4: Autolus Limited
-
Descartes-11: Cartesian Therapeutics
-
BA 3011: BioAtla
And many more
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. CAR T-Cell Therapy Current Treatment Patterns
4. CAR T-Cell Therapy – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. CAR T-Cell Therapy Late-Stage Products (Phase-III)
7. CAR T-Cell Therapy Mid-Stage Products (Phase-II)
8. CAR T-Cell Therapy Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. CAR T-Cell Therapy Discontinued Products
13. CAR T-Cell Therapy Product Profiles
14. Key Companies in the CAR T-Cell Therapy Market
15. Key Products in the CAR T-Cell Therapy Therapeutics Segment
16. Dormant and Discontinued Products
17. CAR T-Cell Therapy Unmet Needs
18. CAR T-Cell Therapy Future Perspectives
19. CAR T-Cell Therapy Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
“Cast Saw Devices Market” research report provides comprehensive insights into the historic and forecasted market size, share, trends, and growth estimation for Cast Saw Devices. It also covers the latest breakthroughs, collaboration, latest innovations, emerging devices, and key companies working in the global Cast Saw Devices market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/